Alector, Inc. (ALEC)

Over the past six months, Alector, Inc.'s stock experienced a 49% plunge in October 2025 after its Phase 3 trial for latozinemab failed, leading to trial discontinuation and workforce reduction. In November 2025, Morgan Stanley cut its price target for Alector stock. In December 2025, insider stock sales were reported, and Neil Berkley was appointed as CFO and CBO. Despite these setbacks, ALEC's stock has shown a 20.0% return over the past six months, with a 52-week range between $0.87 and $3.40.

As a clinical-stage biopharmaceutical company, Alector, Inc. does not have traditional products or services on the market that generate sales, therefore there is no demand seasonality. The company's revenue is derived from collaboration agreements, which are inherently volatile and not subject to seasonal fluctuations.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegeneration by restoring healthy immune function in the brain. The company operates in the Healthcare sector, specifically in Drug Discovery and Biotechnology. Alector's pipeline includes Latozinemab (AL001) in Phase 3 trial for frontotemporal dementia (FTD-GRN), AL002 and AL003, Nivisnebart (AL101/GSK4527226) in Phase 2 trial for early Alzheimer's disease, AL137 (for Alzheimer's disease) and AL050 (for Parkinson's disease), and the Alector Brain Carrier (ABC) platform for enhanced drug delivery across the blood-brain barrier.

Alector, Inc.'s corporate office is located in South San Francisco, California, United States. Its revenue is primarily derived from collaboration agreements, making it global in nature rather than tied to specific geographic regions.

Alector's brand reputation in the past year has been negatively impacted by the failed Phase 3 trial for latozinemab in October 2025, resulting in a stock price drop and workforce reduction. Analysts downgraded the company's outlook to "Neutral", raising concerns about translational biology risks. However, the company continues to advance its Alector Brain Carrier (ABC) platform, which is a key competitive advantage.

Alector, Inc. has a substantial number of institutional owners and shareholders including Fmr Llc, BlackRock, Inc., Rtw Investments, Lp, Vanguard Group Inc, PRHSX - T. Rowe Price Health Sciences Fund, Inc., Merck & Co., Inc., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Acadian Asset Management Llc, Price T Rowe Associates Inc /md/, and IWM - iShares Russell 2000 ETF. Individual owners of company stock include Polaris Venture Management Co, Arnon Rosenthal, Sara Kenkare-Mitra, Neil Lindsay Berkley, Marc Grasso, Gary Romano, Grace Wong-Sarad, Kristine Yaffe, and Paula Hammond.